Archives
New Alzheimer’s drug slows cognitive decline by 35 per cent
4 May 2023
A clinical trial has revealed a new Alzheimer’s drug can successfully slow down decline in memory and thinking by 35 per cent. Donanemab has been shown to significantly reduce cognitive decline in people with early-stage Alzheimer’s disease. The trial by US pharmaceutical company Eli Lilly showed it has been successful in removing sticky amyloid plaques […]
Join Dementia Research volunteers help discover Alzheimer’s drug lecanemab
1 December 2022
The findings of a research study that discovered a treatment for early stage Alzheimer’s disease have been hailed as “momentous” by Alzheimer’s Research UK. The new treatment, lecanemab, is the first drug to slow cognitive decline in people with early signs of the condition. The CLARITY-AD study enrolled 1,795 patients with early-stage Alzheimer’s globally, including Join […]
Lecanemab – a potential new treatment for Alzheimer’s disease
28 September 2022
News that a potential treatment for early stage Alzheimer’s disease can slow cognitive decline is a significant development in dementia research. About the drug Lecanemab is an antibody that is designed to remove toxic beta-amyloid deposits; proteins that build up in the brains of people with Alzheimer’s disease. Following phase 3 clinical trials, pharmaceutical companies […]
Diabetes drug to be tested as a potential treatment for Alzheimer’s disease
7 September 2022
Clinical trials across England and Scotland are underway to investigate if an existing diabetes medicine can potentially work as a disease-modifying option for early-stage Alzheimer’s disease. Novo Nordisk is now working alongside Join Dementia Research to investigate if the medicine, known as semaglutide, could also benefit people living with early Alzheimer’s disease. What the study […]
Clinical study to assess potential Alzheimer’s drug
13 July 2022
There are almost one million people with dementia in the UK and the most common cause is Alzheimer’s disease. Researchers from University College London (UCL) with funding from the National Institute for Health and Care Research are testing a new approach to the treatment of mild Alzheimer’s disease in the DESPIAD (DEpletion of SaP in […]